GPC Biotech

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Retrieved on: 
Tuesday, June 20, 2023
Biotechnology, Technology, Professional Services, Health, Oncology, Health Technology, Research, Data Analytics, Software, Artificial Intelligence, Science, MSD, CRISPR, Drug development, Genomics, Biogen, Intelligence, Bristol Myers Squibb, Genome, Biomarker, Princeton University, Harvard Medical School, Milind, Bayer, GPC Biotech, Genome Therapeutics Corporation, Novartis, Patient, Commercial Affairs Department, MMV, Machine learning, Drug combination, Corporation, Drug discovery, Sanofi, Faculty, Entrepreneurship, Merck, AI, Merck & Co., Bavarian Nordic, Massachusetts General Hospital, Therapy, Medical device, Pharmaceutical industry, Management, Turbine

This investment brings the company’s oversubscribed Series A round to €25.5 million and adds further U.S.-based investors to the company’s financing syndicate.

Key Points: 
  • This investment brings the company’s oversubscribed Series A round to €25.5 million and adds further U.S.-based investors to the company’s financing syndicate.
  • Alongside the funding, Turbine announced the appointments of four independent directors to its board.
  • They also have the capacity to perform assays that would be impractical to conduct at scale and with high throughput.
  • Dr. Wegner believes Turbine’s pairing of AI with advanced biotechnology gives it potential to powerfully impact the future of healthcare.

Aspira Women’s Health Names Torsten Hombeck as Chief Financial Officer

Retrieved on: 
Tuesday, May 16, 2023
Woman, Gynaecology, Business administration, GPC Biotech, Acquisition, Risk, Child, CFO, Ovarian cancer, Therapy, Master of Business Administration, Management, Finance, Aspira

AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has appointed Torsten Hombeck, Ph.D., as Chief Financial Officer, replacing interim CFO Marlene McLennan.

Key Points: 
  • AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has appointed Torsten Hombeck, Ph.D., as Chief Financial Officer, replacing interim CFO Marlene McLennan.
  • “We are pleased to welcome Torsten to the Aspira management team as our new CFO,” said Nicole Sandford, President and Chief Executive Officer of Aspira Women’s Health.
  • His previous positions include Chief Commercial and Strategy Officer and Managing Director at Promethera Biosciences, and Co-Chief Executive Officer and Chief Business Officer at Cytonet where he played an integral role in its acquisition by Promethera.
  • Dr. Hombeck also served as Chief Financial Officer at both Agennix and GPC Biotech.

Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, May 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, PD, Senior, Investment, Abbott Laboratories, DHEAS, G&A, A4, Patient, Risk, Androstenedione, Research and development, R, SVP, Disease, University, Keck School of Medicine of USC, Clinical trial, Glucocorticoid, CAH, Spruce, Pharmacokinetics, Astex Pharmaceuticals, Growth, Biostatistics, Safety, Puberty, Statistics, Business operations, Adrenocorticotropic hormone, Public health, Administration, PCOS, Adolescence, GBT, ACTH, Therapy, Pfizer, Congenital adrenal hyperplasia, Medicine, Drug, Woman, PES, Annual general meeting, Public expenditure, Novartis, GPC Biotech, Strategic partnership, Female, Pharmaceutical industry, Nursing, Adult, Cycloheximide, Pediatrics, Biometrics, Probability

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates.
  • “I am pleased by the meaningful progress Spruce made across our clinical and business objectives in the first quarter of 2023.
  • Additionally, we have completed enrollment in our P.O.W.E.R study for PCOS and will be reporting topline data in the third quarter," said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences.
  • Spruce remains on track to report topline data from adolescents (cohorts 1 and 2) in the second half of 2023.

Dayton Therapeutics Discovers New Therapeutic Uses of Satraplatin for Treatment of Rare Lymphomas

Retrieved on: 
Wednesday, September 14, 2022
Nervous system, Satraplatin, Carboplatin, Molecular biology, FDA, Lymphoma, Cisplatin, Stroke, Therapy, Patient, Genetics, Cancer, CEO, Technology, United States dollar, DNA repair, Research, DNA, Prostate cancer, Lymphatic system, Platinum, GPC Biotech, AI, Patent, Oncology, Toxicity, Pharmaceutical industry

Dayton Therapeutics is now investigating development of satraplatin for the treatment of rare lymphomas and as an outcome of the research that Dayton Therapeutics has conducted, the company has already filed two patent applications for strong IP protection.

Key Points: 
  • Dayton Therapeutics is now investigating development of satraplatin for the treatment of rare lymphomas and as an outcome of the research that Dayton Therapeutics has conducted, the company has already filed two patent applications for strong IP protection.
  • In 2020, Dayton Therapeutics, a firm led by a team of experienced oncologists, acquired all satraplatin related rights and data.
  • Dayton Therapeutics is a clinical oncology company that specializes in the identification of compounds for the treatment of new cancer indications with limited therapeutic options.
  • The company is currently leveraging proprietary oncologist know-how, AI and data mining to develop satraplatin as a precision platinum for the treatment of rare lymphomas.

Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.

Retrieved on: 
Tuesday, September 13, 2022
Risk, VP, TSX, Director, Lymphatic system, Genome, Company, Hematology, Industry, Massachusetts General Hospital, MDS, Patient, Exchange, CEO, Bristol Myers Squibb, Acute myeloid leukemia, Toxic epidermal necrolysis, CSO, APS, Bioinvent, NASDAQ, Princeton University, Harvard Medical School, SAN, Board, Biotechnology, AML, GLOBE, GPC Biotech, Pharmaceutical industry, Management

Aptoses Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development.

Key Points: 
  • Aptoses Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development.
  • He is Chairman of the Board of Directors for Oxford Biotherapeutics (U.K.) and serves in board positions for Aprea (Sweden), Oncolytics (Canada), Vaccibody (Norway), and BioInvent (Sweden).
  • We very much look forward to working with him and having him lend his insight and vast global biopharmaceutical experience to Aptose as a member of our Board of Directors.
  • I am excited to join the Aptose Board at such a pivotal time in the companys evolution, said Dr. Seizinger.

Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer

Retrieved on: 
Thursday, June 16, 2022
Doctor of Philosophy, Immunology, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, University of Helsinki, Astellas Pharma, Transplant, GPC Biotech, MBA, Vaccine, CBO, Bristol Myers Squibb, CEO, Potyvirus, Valo, Rutgers University, Cancer, Transgene, University, Virus, Infection, Buffalo, Neo, Marketing, Program, Pharmacy, COO, Therapy, Immunotherapy, Pharmaceutical industry

HELSINKI, June 16, 2022 /PRNewswire/ -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of Dr Hemanshu Shah as Chief Business Officer (CBO), based in the US.

Key Points: 
  • HELSINKI, June 16, 2022 /PRNewswire/ -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of Dr Hemanshu Shah as Chief Business Officer (CBO), based in the US.
  • ValoTx's CEO, Paul Higham, said, "I am delighted to welcome Dr Hemanshu Shah as our CBO.
  • He'll be making the most of the substantial business development opportunities represented by our unique cancer and infectious disease immunotherapy platforms.
  • Dr Hemanshu Shah has a deep heritage in business development and corporate development transactions, coupled with US and global marketing experience.

Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer

Retrieved on: 
Thursday, June 16, 2022
Doctor of Philosophy, Immunology, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, University of Helsinki, Astellas Pharma, Transplant, GPC Biotech, MBA, Vaccine, CBO, Bristol Myers Squibb, CEO, Potyvirus, Valo, Rutgers University, Cancer, Transgene, University, Virus, Infection, Buffalo, Neo, Marketing, Program, Pharmacy, COO, Therapy, Immunotherapy, Pharmaceutical industry

HELSINKI, June 16, 2022 /PRNewswire/ -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of Dr Hemanshu Shah as Chief Business Officer (CBO), based in the US.

Key Points: 
  • HELSINKI, June 16, 2022 /PRNewswire/ -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of Dr Hemanshu Shah as Chief Business Officer (CBO), based in the US.
  • ValoTx's CEO, Paul Higham, said, "I am delighted to welcome Dr Hemanshu Shah as our CBO.
  • He'll be making the most of the substantial business development opportunities represented by our unique cancer and infectious disease immunotherapy platforms.
  • Dr Hemanshu Shah has a deep heritage in business development and corporate development transactions, coupled with US and global marketing experience.

Akari Therapeutics Announces Appointment of Chief Financial Officer

Retrieved on: 
Wednesday, July 1, 2020
GPC Biotech, Chief business officer, Chief financial officer, Leadership, Business, Companies

Torsten brings a deep understanding of financial strategy, the capital markets and business development to Akari.

Key Points: 
  • Torsten brings a deep understanding of financial strategy, the capital markets and business development to Akari.
  • His business and financial expertise will be instrumental in helping us to further develop the Company, said Clive Richardson, Chief Executive Officer of Akari Therapeutics.
  • His previous positions include Chief Commercial and Strategy Officer and Managing Director at Promethera Biosciences, a private biopharmaceutical company, and Co-Chief Executive Officer and Chief Business Officer at Cytonet where he played an integral role in its acquisition by Promethera in 2016.
  • Dr. Hombeck also served as Chief Financial Officer at both Agennix and GPC Biotech.

Metastatic Hormone Refractory Prostate Cancer Pipeline Insight, 2019 - Complete Product Development Cycle Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2019
Health, Oncology, Pharmaceutical, Cancer, Histopathology, Prostate cancer, RTT, Neoplasms, GPC Biotech, Tasquinimod

The "Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Metastatic Hormone Refractory Prostate Cancer development.
  • The report assesses the active Metastatic Hormone Refractory Prostate Cancer pipeline products by developmental stage, product type, molecule type, and administration route.
  • clinical, pre-clinical and discovery stages for the Metastatic Hormone Refractory Prostate Cancer
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Metastatic Hormone Refractory Prostate Cancer